ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and ...

Focal Segmental Glomerulosclerosis Market Outlook. Focal Segmental Glomerulosclerosis (FSGS), encompassing diverse conditions like CAD, PAD, and cerebrovascular disease, all rooted in atherosclerosis.

Focal segmental glomerulosclerosis (FSGS) still lacks an FDA-approved therapy, but late-breaking post hoc results from the phase III DUPLEX trial -- presented at the National Kidney Foundation ...

Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. The New England Journal of Medicine. Published online November 3, 2023. doi:10.1056 ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.

Chronic kidney disease (CKD) is typically associated with severe fibrosis, the exact pathogenesis of which remains unclear.

Background. Focal and segmental glomerulosclerosis (FSGS) is the most common histologic pattern of renal injury seen in adults with idiopathic proteinuria. Homozygous or compound heterozygous ...

Armistice Capital holds 8.9M shares in Travere Therapeutics as rare kidney disease stock climbs 110% following FILSPARI's ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often and more quickly on sparsentan (Filspari) than irbesartan (Avapro ...

Focal segmental glomerulosclerosis (FSGS) is a kidney disease that leads to renal failure, and it affects individuals from different ancestries, the highest prevalence being among African and African ...

A 51-year-old man with a history of non–ST-segment elevation myocardial infarction, hypertension, and focal segmental glomerulosclerosis (FSGS) was admitted to a hospital due to worsening renal ...